Saturday 17 October 2026 Export NOTVQ’s income statement to Excel — free account

Inotiv, Inc.

Inotiv, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $513.0 million, up 4.54% from fiscal 2024. In the quarter to March 2026, revenue fell 5.37%, EPS fell 113.6%, free cash flow grew 82.7% and total debt rose 5.98%, each against the same quarter a year earlier.

0.01 0.00 0.00%

Follow NOTVQ

Alert me

Market cap: $2.8M
P/E: 0.0×
Fwd P/E: −0.1×
Dividend yield: —
F-score: 5/9
Altman Z: −1.13
Beneish M: −2.85
Dividend safety: n/a

Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.07

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	1	—	4	—	—	—	—	—	—	—	—

Insider Ownership 9.21%

Capital & Financial Ratios $m

Market Cap 2.79

Revenue 507.36

Net Income (86.97)

Free Cash Flow (9.90)

Net Debt 408.24

Current Ratio 0.27

Debt/Equity 5.49

P/E ratio 0.00

Fwd P/E (0.08)

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (7.35%)

Next Y EPS Growth 20.09%

Next Y revenue growth 3.21%

Next 5Y EPS Growth 77.23%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	35	21	22	15
Receivables	87	74	78	61
Inventory	56	18	46	31
Other	1	—	—	—
	214	163	195	144

	2023	2024	2025	Q'26
Payables	33	34	49	38
ST’ Debt	8	4	405	423
Other	56	42	52	38
	132	119	557	540

Compound Annual Growth %

	10y	5y	3y
Sales	36.59%	53.36%	(2.15%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	28.92%	78.08%	(27.69%)

Revenue $m

	Dec	Mar	Jun	Sep	Year
’26	121	118	—	—	—
’25	120	124	131	138	513
’24	136	119	106	130	491
’23	123	151	157	141	572
’22	84	140	173	150	548
’21	18	19	23	30	90
’20	13	16	16	16	60

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(5)	(1)	—	—	—
’25	(4)	(13)	(7)	14	(10)
’24	(7)	17	(15)	(2)	(7)
’23	(7)	13	4	19	28
’22	(1)	5	(9)	0	(5)
’21	2	3	4	3	11
’20	1	(1)	1	0	1

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(11)	(3)	—	—	—
’25	(9)	(18)	(10)	14	(23)
’24	(11)	12	(18)	(8)	(24)
’23	(16)	4	(1)	13	1
’22	(7)	(4)	(25)	(5)	(41)
’21	0	2	(2)	(1)	(2)
’20	(1)	(2)	(1)	(1)	(5)

Fiscal quarters ending in the months shown.

EPS $

	Dec	Mar	Jun	Sep	Year
’26	(0.83)	(0.94)	—	—	—
’25	(1.02)	(0.44)	(0.51)	(0.25)	(2.11)
’24	(0.60)	(1.86)	(1.00)	(0.73)	(4.19)
’23	(3.41)	(0.39)	0.07	(0.38)	(4.10)
’22	(3.93)	(0.24)	(0.15)	(9.54)	(13.84)
’21	(0.03)	(0.06)	0.17	0.71	0.79
’20	(0.13)	(0.05)	(0.08)	(0.16)	(0.43)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	0.60	0.65	1.18	1.26	3.05	11.11	3.65	1.61	1.23	0.47	Analyst estimates 2026–2028 Powerpack
	High	1.70	2.95	2.60	5.43	12.43	60.66	42.78	8.88	11.42	5.67
People
People	Employees	151	155	235	322	421	567	2,204	2,055	2,075	2,046
	Revenue/emp, $m	0.14	0.16	0.11	0.14	0.14	0.16	0.25	0.28	0.24	0.25
Income, $m
Income, $m	Revenue	20	24	26	44	60	90	548	572	491	513
	Gross margin, %	21.65	31.75	30.81	32.18	30.16	33.65	28.71	31.78	22.65	23.58
	EBT	(3)	1	0	(1)	(5)	6	(352)	(124)	(131)	(88)
	EBT margin, %	(15.87)	3.75	(0.96)	(1.80)	(7.50)	6.83	(64.36)	(21.70)	(26.65)	(17.11)
	Net income	(3)	1	0	(1)	(5)	11	(337)	(105)	(109)	(69)
	Depreciation	3	2	2	3	4	6	52	58	61	61
Per share, $
Per share, $	Revenue	2.52	2.96	3.00	4.20	5.57	6.79	22.49	22.32	18.95	15.81
	Earnings	(0.40)	0.11	(0.02)	(0.08)	(0.43)	0.83	(13.84)	(4.10)	(4.19)	(2.11)
	Cash flow	0.13	0.15	0.40	0.17	0.12	0.81	(0.21)	1.09	(0.26)	(0.32)
	Capex	(0.15)	(0.04)	(0.15)	(0.66)	(0.57)	(0.95)	(1.48)	(1.03)	(0.65)	(0.40)
	Free cash flow	(0.02)	0.11	0.25	(0.49)	(0.45)	(0.13)	(1.69)	0.06	(0.91)	(0.72)
	Book value	0.92	1.04	1.24	1.03	0.70	7.97	14.77	10.47	6.58	4.19
	Shares, m	8	8	9	10	11	13	24	26	26	32
Valuation, ×
Valuation, ×	P/E	0.00	16.09	0.00	0.00	0.00	43.16	0.00	0.00	0.00	0.00
	P/S	0.46	0.60	0.55	0.85	0.86	4.30	0.75	0.13	0.09	0.09
	P/B	1.49	1.95	1.34	3.49	6.85	3.67	1.14	0.28	0.26	0.35
	EV/Sales	0.69	0.76	0.88	1.22	1.29	4.40	1.36	0.73	0.85	1.60
	EV/FCF	(72.19)	20.62	10.72	(10.44)	(15.87)	(228.77)	(18.07)	280.04	(17.60)	(35.16)
Cash, $m
Cash, $m	Operating cash flow	1	1	3	2	1	11	(5)	28	(7)	(10)
	Capex	(1)	0	(1)	(7)	(6)	(12)	(36)	(26)	(17)	(13)
	Free cash flow	0	1	2	(5)	(5)	(2)	(41)	1	(24)	(23)
Balance, $m
Balance, $m	Working capital	(9)	(2)	(4)	(5)	(16)	134	69	82	44	(362)
	Total debt	5	4	9	17	27	166	354	378	393	405
	Net debt	5	4	9	16	26	9	335	342	372	383
	Shareholders’ equity	7	8	11	11	8	105	360	268	171	136
Returns, %
Returns, %	ROA	(14.37)	4.26	(0.75)	(2.16)	(9.05)	5.68	(52.46)	(11.56)	(13.24)	(8.84)
	ROIC	(15.47)	6.40	0.04	(0.36)	(5.69)	(3.08)	(23.71)	(8.34)	(9.96)	(3.72)
	ROE	(40.84)	12.90	(2.12)	(7.34)	(51.35)	19.33	(144.99)	(33.47)	(49.41)	(44.78)

Negative figures in brackets.

All 10 years →

Fiscal years to Sep 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NDRA ENDRA Life Sciences Inc.	$7.7M	— (loss-making)	— (loss-making)	−98.80% (below 0%: shrinking)	n/m	+15.04% (above 0%: growing)	0.00%	0.00%	Compare
XWEL XWELL, Inc.	$7.5M	— (loss-making)	— (loss-making)	−7.08% (below 0%: shrinking)	n/m	−43.02% (below 0%: shrinking)	41.26%	(29.45%)	Compare
TTOO T2 Biosystems, Inc.	$6.5M	— (loss-making)	— (loss-making)	+34.85% (above 0%: growing)	n/m	+53.36% (above 0%: growing)	(106.60%)	(511.89%)	Compare
BIAF bioAffinity Technologies, Inc.	$5.1M	— (loss-making)	— (loss-making)	+18.99% (above 0%: growing)	n/m	−23.69% (below 0%: shrinking)	27.98%	(220.77%)	Compare
DMTKQ DermTech, Inc.	$3.3M	— (loss-making)	— (loss-making)	+10.58% (above 0%: growing)	n/m	+24.87% (above 0%: growing)	18.54%	(533.37%)	Compare
NOTVQ Inotiv, Inc.	$2.8M	— (loss-making)	— (loss-making)	−5.37% (below 0%: shrinking)	n/m	+82.66% (above 0%: growing)	20.95%	(16.41%)
ISPC iSpecimen Inc.	$2.6M	— (loss-making)	— (loss-making)	−78.70% (below 0%: shrinking)	n/m	−257.73% (below 0%: shrinking)	45.23%	(897.30%)	Compare
AWHL Aspira Women's Health Inc.	$2.4M	— (loss-making)	— (loss-making)	−14.89% (below 0%: shrinking)	n/m	−24.57% (below 0%: shrinking)	55.28%	(89.69%)	Compare
PRPH ProPhase Labs, Inc.	$1.2M	— (loss-making)	— (loss-making)	−18.93% (below 0%: shrinking)	n/m	+56.67% (above 0%: growing)	22.35%	(261.62%)	Compare
Median of peers	$4.2M	—	—	−10.98%	—	−4.32%	25.17%	(241.19%)

All 52 Diagnostics & Research stocks →

Inotiv, Inc. (NOTVQ) key facts

Strength: Inotiv, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $513.0 million, up 4.54% from fiscal 2024.
Inotiv, Inc. (NOTVQ) is a Diagnostics & Research company in the Healthcare sector.
As of July 27, 2026, NOTVQ traded at $0.01, a market capitalization of $2.8 million.
Return on equity was −44.8% and debt-to-equity 5.49.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −1.13 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.